Marker Therapeutics inc (MRKR) - News Archive

Strategic Infusion: Marker Therapeutics’ $16.1 Million Private Placement Fuels Hope for Lymphoma TreatmentMarker Therapeutics, a frontrunner in the realm of cell therapies, has announced a significant milestone with a p...

In the realm of oncology, breakthroughs in treatment options can significantly alter the landscape of patient care and outcomes. A recent clinical update from Marker Therapeutics Inc. highlights encouraging developments...

The 11th Global Summit on Hematologic Malignancies held in Whistler, BC, Canada, served as a platform for leading experts in the field to discuss and share the latest advancements in the treatment of blood cancers. Amon...

HOUSTON, Jan. 22, 2024. Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company, has achieved a significant scientific milestone, even as it contends with financial setbacks. The advanced biot...

Marker Therapeutics, a leading bio-pharmaceutical firm, recently announced vital updates and strategic prioritization of its clinical programs with concentrated focus on MT-601 in patients diagnosed with lymphoma. This...

In a significant breakthrough for the field of immunotherapy, Marker Therapeutics Inc. recently announced a sustained complete response in the first lymphoma patient treated with MT-601 following a relapse from CAR T ce...